CLL-638 Latest Results From an Ongoing Firstin-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell Malignancies
Kim Linton(The Christie NHS Foundation Trust), Alexey V. Danilov(Dartmouth–Hitchcock Medical Center), Jeanette K. Doorduijn(Université Paris Cité), Ganesh Cherala(Nurix (United States)), Allison Winter(Cleveland Clinic), Srinand Nandakumar(Nurix (United States)), Talha Munir(Leeds Teaching Hospitals NHS Trust), Pam McKay(Beatson West of Scotland Cancer Centre), David Lewis(Derriford Hospital), Karan Dixit(Northwestern University), Erin Meredith(Nurix (United States)), Sarah G. Injac(Baylor College of Medicine), Francesco Forconi(University of Leeds), Dima El‐Sharkawi(Royal Marsden Hospital), Zulfa Omer(University of Cincinnati), Alvaro J. Alencar(University of Miami), Nirav N. Shah(Medical College of Wisconsin), Mary Gleeson(Sarah Cannon Research Institute), Graham P. Collins(Churchill Hospital), John C. Riches(Queen Mary University of London), May Tan(Nurix (United States)), Ted Shih(Nurix (United States))
Cited by 2
Related Papers
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
|Blood|2020|657
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
|The Lancet|2021|454